Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Call Transcript

Page 3 of 3

Scott Davis: Right. Thank you, Diego, and thanks to everyone joining us today. Overall, 2023 was a momentous year for Ekso Bionics highlighted by record revenue growth. For our EksoHealth business, our go-to-market strategy enabled us to drive more multiunit orders from network operators that helped us achieve our strong revenue growth and improve our operating leverage. Now that we’ve added GaitCoach software to EksoNR devices, we are addressing patient rehab needs by bringing these latest innovations to our exoskeleton devices. From an operations perspective, we continue to optimize our expense and inventory management processes, which are being designed to enable us to scale our business and grow more efficiently. Looking forward, we’re optimistic about our 2024 business outlook and are excited as we build up the momentum generated — as we build upon the momentum that was generated in 2023.

We’re looking forward to providing updates on our continued progress, and we thank you all for joining us today. Have a great day.

Operator: Thank you. This concludes today’s conference. All parties may disconnect. Have a good day.

Follow Ekso Bionics Holdings Inc. (NASDAQ:EKSO)

Page 3 of 3